Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer

M. G. Kris, R. J. Gralla, D. P. Kelsen, E. S. Casper, M. T. Burke, J. J. Fiore, I. R. Cibas, R. T. Heelan

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

4-Demethoxydaunorubicin (4-DMDR) is an orally active analog of daunorubicin that in preclincial testing has demonstrated greater antitumor activity and less cardiotoxicity than its parent compound. Thirty-two patients with metastatic non-small cell lung cancer received 4-DMDR at a dose of 40-50 mg/m2 orally every 21 days. Thirteen patients had received no prior chemotherapy. Among the 30 adequately treated patients, one major response lasting 5.2 months was observed. Leukopenia 10-14 days after treatment was the most commonly observed toxicity. With an overall observed major response rate of 3.3% in 30 patients, the predicted true response rate is ≤16% (p = 0.05). At the dose and schedule studied in this group of patients with non-small cell lung cancer, 4-DMDR had only marginal activity.

Original languageEnglish (US)
Pages (from-to)377-379
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume8
Issue number5
DOIs
Publication statusPublished - Jan 1 1985

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this